{"id":"lu-aa21004","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines inhibition of serotonin reuptake (increasing synaptic serotonin) with direct agonism at the 5-HT1A autoreceptor (which enhances serotonergic neurotransmission) and antagonism at the 5-HT7 receptor (which may contribute to antidepressant and anxiolytic effects). This multimodal mechanism is designed to provide faster onset and improved efficacy compared to selective serotonin reuptake inhibitors alone.","oneSentence":"Lu AA21004 is a multimodal antidepressant that acts as a serotonin reuptake inhibitor, serotonin 5-HT1A receptor agonist, and serotonin 5-HT7 receptor antagonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:43.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT07000734","phase":"PHASE2","title":"Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-07-28","conditions":"Aging, Cognitive Decline, Older Adults","enrollment":20},{"nctId":"NCT02357797","phase":"PHASE4","title":"Adjunctive Vortioxetine in Schizophrenia","status":"UNKNOWN","sponsor":"Northwell Health","startDate":"2016-02","conditions":"Schizophrenia, Negative Symptoms","enrollment":88},{"nctId":"NCT05481957","phase":"PHASE4","title":"Vortioxetine Adjunctive Treatment in Bipolar Depression","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-03-01","conditions":"Bipolar Depression","enrollment":131},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT04301492","phase":"PHASE4","title":"Tolerability, Safety and Efficacy of Vortioxetine","status":"UNKNOWN","sponsor":"IRCCS San Raffaele Roma","startDate":"2019-11-20","conditions":"Depression","enrollment":20},{"nctId":"NCT03779789","phase":"PHASE4","title":"Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2019-02-01","conditions":"Major Depressive Disorder","enrollment":362},{"nctId":"NCT05417087","phase":"PHASE1","title":"Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets","status":"COMPLETED","sponsor":"Seasons Biotechnology (Taizhou) Co., Ltd.","startDate":"2022-06-27","conditions":"Major Depressive Disorder (MDD)","enrollment":48},{"nctId":"NCT05014919","phase":"PHASE3","title":"Vortioxetine to Prevent Return of Symptoms in Children With Depression","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2021-08-10","conditions":"Depression","enrollment":35},{"nctId":"NCT02871297","phase":"PHASE3","title":"Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2016-08-17","conditions":"Depressive Disorder, Major","enrollment":662},{"nctId":"NCT02709655","phase":"PHASE3","title":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-05-18","conditions":"Depressive Disorder, Major","enrollment":683},{"nctId":"NCT03108625","phase":"PHASE3","title":"Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2017-03-01","conditions":"Depressive Disorder, Major","enrollment":94},{"nctId":"NCT02389816","phase":"PHASE3","title":"A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-04-10","conditions":"Major Depressive Disorder","enrollment":493},{"nctId":"NCT02371980","phase":"PHASE4","title":"Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-02-10","conditions":"Major Depressive Disorder","enrollment":1106},{"nctId":"NCT02528409","phase":"PHASE2","title":"Vortioxetine for Binge Eating Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2016-06","conditions":"Binge Eating Disorder","enrollment":80},{"nctId":"NCT02709746","phase":"PHASE3","title":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-05","conditions":"Depressive Disorder, Major","enrollment":784},{"nctId":"NCT03835715","phase":"PHASE4","title":"Study With Vortioxetine on Emotional Functioning in Patients With Depression","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2019-02-05","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT04253678","phase":"","title":"Vortioxetine for Cancer Patients With Depression: An Observational Study","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2019-12-12","conditions":"Major Depressive Disorder, Cancer","enrollment":140},{"nctId":"NCT02969876","phase":"PHASE4","title":"Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-08-24","conditions":"Depressive Disorder, Major Depression, Depression","enrollment":2},{"nctId":"NCT03766867","phase":"PHASE2","title":"Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-12-03","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT02972632","phase":"PHASE4","title":"Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Major Depressive Disorder","enrollment":123},{"nctId":"NCT03437564","phase":"PHASE1","title":"A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-16","conditions":"Healthy Adult Participants","enrollment":28},{"nctId":"NCT03978286","phase":"PHASE4","title":"Vortioxetine vs Sertraline in Mexicans","status":"COMPLETED","sponsor":"Universidad Juárez Autónoma de Tabasco","startDate":"2016-06-30","conditions":"Depression, Type 2 Diabetes Mellitus","enrollment":21},{"nctId":"NCT03187093","phase":"PHASE4","title":"Cognitive Dysfunction in MDD Patients","status":"UNKNOWN","sponsor":"Oleg Levada","startDate":"2016-10","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT03598868","phase":"PHASE2","title":"Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-08-08","conditions":"Bipolar Disorder Depression","enrollment":100},{"nctId":"NCT02327013","phase":"PHASE2","title":"Investigating the Effect of Vortioxetine in Adult ADHD Patients","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-12","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":227},{"nctId":"NCT02279953","phase":"PHASE3","title":"Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-10","conditions":"Major Depressive Disorder","enrollment":151},{"nctId":"NCT01491035","phase":"PHASE2","title":"Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-04","conditions":"Depressive Disorder, Anxiety Disorder","enrollment":48},{"nctId":"NCT02272517","phase":"PHASE3","title":"Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-12","conditions":"Major Depressive Disorder","enrollment":101},{"nctId":"NCT02279966","phase":"PHASE3","title":"Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-10","conditions":"Major Depressive Disorder","enrollment":152},{"nctId":"NCT02454426","phase":"EARLY_PHASE1","title":"Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2016-04","conditions":"Major Depressive Disorder, Coronary Artery Disease","enrollment":""},{"nctId":"NCT02294305","phase":"PHASE4","title":"Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder","status":"UNKNOWN","sponsor":"The Medical Research Network","startDate":"2014-12","conditions":"Social Anxiety Disorder, Major Depressive Disorder","enrollment":40},{"nctId":"NCT02170220","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-07","conditions":"Severe Hepatic Impairment","enrollment":12},{"nctId":"NCT02072278","phase":"PHASE1","title":"Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-02","conditions":"Healthy Men","enrollment":32},{"nctId":"NCT00788034","phase":"PHASE3","title":"Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-10","conditions":"Generalized Anxiety Disorder","enrollment":459},{"nctId":"NCT02386488","phase":"PHASE1","title":"Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Pharmacokinetics","enrollment":64},{"nctId":"NCT01564862","phase":"PHASE2","title":"Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-04","conditions":"Depressive Disorder, Major","enrollment":602},{"nctId":"NCT01355081","phase":"PHASE3","title":"Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-05","conditions":"Major Depressive Disorder","enrollment":366},{"nctId":"NCT01571453","phase":"PHASE3","title":"Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-05","conditions":"Major Depressive Disorder","enrollment":437},{"nctId":"NCT01364649","phase":"PHASE3","title":"Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-06","conditions":"Treatment Outcome","enrollment":447},{"nctId":"NCT01422213","phase":"PHASE3","title":"Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-12","conditions":"Major Depressive Disorder","enrollment":598},{"nctId":"NCT01152996","phase":"PHASE3","title":"Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-09","conditions":"Depressive Disorder, Major","enrollment":1075},{"nctId":"NCT00839423","phase":"PHASE2","title":"Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2006-08","conditions":"Major Depressive Disorder","enrollment":426},{"nctId":"NCT00694304","phase":"PHASE3","title":"Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-05","conditions":"Major Depressive Disorder","enrollment":535},{"nctId":"NCT00596817","phase":"PHASE3","title":"Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-12","conditions":"Major Depressive Disorder","enrollment":639},{"nctId":"NCT01488071","phase":"PHASE3","title":"A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-01","conditions":"Major Depressive Disorder","enrollment":495},{"nctId":"NCT00744627","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-09","conditions":"Generalized Anxiety Disorder","enrollment":301},{"nctId":"NCT00635219","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-02","conditions":"Major Depressive Disorder","enrollment":766},{"nctId":"NCT01140906","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2010-05","conditions":"Major Depressive Disorder","enrollment":607},{"nctId":"NCT01323478","phase":"PHASE3","title":"Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-04","conditions":"Major Depressive Disorder","enrollment":71},{"nctId":"NCT00811252","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2009-01","conditions":"Major Depressive Disorder","enrollment":453},{"nctId":"NCT00761306","phase":"PHASE2","title":"Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-06","conditions":"Major Depressive Disorder","enrollment":74},{"nctId":"NCT00672620","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Major Depressive Disorder","enrollment":611},{"nctId":"NCT00734071","phase":"PHASE3","title":"An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":304},{"nctId":"NCT01163266","phase":"PHASE3","title":"Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-07","conditions":"Depressive Disorder, Major","enrollment":462},{"nctId":"NCT01255787","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-11","conditions":"Depressive Disorder, Major","enrollment":600},{"nctId":"NCT01179516","phase":"PHASE3","title":"Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-08","conditions":"Depressive Disorder, Major","enrollment":469},{"nctId":"NCT00731120","phase":"PHASE3","title":"Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":457},{"nctId":"NCT01153009","phase":"PHASE3","title":"Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-06","conditions":"Depressive Disorder, Major","enrollment":614},{"nctId":"NCT00730691","phase":"PHASE3","title":"Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":781},{"nctId":"NCT00735709","phase":"PHASE3","title":"Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":560},{"nctId":"NCT01299805","phase":"PHASE1","title":"Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Healthy","enrollment":17},{"nctId":"NCT00672958","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00707980","phase":"PHASE3","title":"Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Major Depressive Disorder","enrollment":836},{"nctId":"NCT01395147","phase":"PHASE3","title":"Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-07","conditions":"Major Depressive Disorder","enrollment":119},{"nctId":"NCT01607125","phase":"PHASE1","title":"Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-07","conditions":"Depression","enrollment":96},{"nctId":"NCT01676571","phase":"PHASE1","title":"Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-10","conditions":"Healthy","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vortioxetine"],"phase":"phase_3","status":"active","brandName":"Lu AA21004","genericName":"Lu AA21004","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lu AA21004 is a multimodal antidepressant that acts as a serotonin reuptake inhibitor, serotonin 5-HT1A receptor agonist, and serotonin 5-HT7 receptor antagonist. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}